0.05Open0.22Pre Close110 Volume23 Open Interest5.00Strike Price550.00Turnover4161.31%IV12.23%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.1420Delta0.3437Gamma112.80Leverage Ratio-25.7555Theta0.0000Rho-16.01Eff Leverage0.0000Vega
Kyverna Therapeutics Stock Discussion
Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome
Kyverna Therapeutics (KYTX) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for KYV-101, its autologous CD19 CAR T-cell therapy, in treating refractory stiff-person syndrome. This designation, based on positive clinical outcomes in Germany, allows Kyverna to receive expert guidance on efficient ...
No comment yet